**Dr. Gili Hart** is a biotech executive serving as the CEO of SpilSense (2020 to the present). Dr. Hart has exstensive experience in preclinical, clinical and global regulatory strategic planning, partnering with large-pharma, and financing. In addition, she brings broad experience in managing critical global programs ranging from discovery phase through Phase 3 clinical trials.

Prior to SpliSense, Dr. Hart served as CEO of Mitoconix Bio (2017-2019). She also served as General Manager of OPKO Biologics (2014 - 2017) and as VP of Pre-clinical and Clinical Pharmacology at PROLOR Biotech during 2007 -2013.

During 2005-2007, Dr. Hart was a Research Fellow at Yale University’s School of Medicine. She received cum laude PhD and MSc degrees from the Weizmann institute of science and graduated *summa cum laude* from the Technion with a Biotechnology Engineering degree.

Dr. Hart published numerous papers and patents, her scientific work focused on autoimmunity diseases as well as on B and T cell maturation and migration that can directly affect inflammation and immune conditions.